WUXI BIO announced today that it has reached a research service cooperation agreement with Candid Therapeutics (referred to as Candid). Candid is a clinical-stage biotechnology company dedicated to becoming a leader in T cell engager (TCE) therapies for autoimmune and inflammatory diseases. According to the agreement, Candid will hold global rights to a trispecific antibody that is in the preclinical development stage. This antibody is based on WUXI BIO's universal multi-specific antibody patent technology platform, WuXiBody. WUXI BIO will receive an upfront payment and will be eligible to receive development and sales milestone payments, totaling up to 0.925 billion USD, as well as sales royalties after the product is launched.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
CA
MY
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
On the first day, the Auntie in Shanghai saw oversubscription exceeding a hundred times! Hong Kong stock tea beverage stocks rose collectively.
In the morning, big news! Alibaba releases and open sources Qwen3, seamlessly integrating thinking modes, multilingual capabilities, and facilitating agent calls.
HSBC Holdings' pre-tax profit for Q1 is 9.484 billion USD, a year-on-year decline of 25%.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
药明生物和Candid Therapeutics就T细胞衔接子三特异性抗体达成研究服务合作
WUXI BIO and Candid Therapeutics have reached a research service collaboration on T-cell bridging trispecific antibodies.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 241
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report